UY31520A1 - Proteinas de union a antigenos - Google Patents

Proteinas de union a antigenos

Info

Publication number
UY31520A1
UY31520A1 UY31520A UY31520A UY31520A1 UY 31520 A1 UY31520 A1 UY 31520A1 UY 31520 A UY31520 A UY 31520A UY 31520 A UY31520 A UY 31520A UY 31520 A1 UY31520 A1 UY 31520A1
Authority
UY
Uruguay
Prior art keywords
beta
aminoid
amiloid
antigen binding
binding proteins
Prior art date
Application number
UY31520A
Other languages
English (en)
Inventor
Wattam Trevor Anthony Kenneth
Thomas Pamela Joan
Soden Peter Ernest
Lewis Alan Peter
Germaschewski Volker
Ford Susannah Karen
Ellis Jonathan Henry
Alard Philippe Marc Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40547800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31520(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0724185A external-priority patent/GB0724185D0/en
Priority claimed from GB0806230A external-priority patent/GB0806230D0/en
Application filed filed Critical
Publication of UY31520A1 publication Critical patent/UY31520A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Proteínas de union a antígenos que se unen a péptido B(Beta)-amiloide, en particular péptido B(Beta)-amiloide humano; procedimeintos de tratar enfermedades o trastornos que se caracterizan por niveles de B(Beta)-amiloide o depositos de B-amiloide elevados, en particular enfermedad de Alzheimer y enfermedades o trastornos que afectan al ojo o al nervio optico que se caracterizan por niveles de B(Beta)-amiloide o depositos de B(Beta)-amiloide elevados, que incluyen degeneracion macular senil y enfermedades de tipo glaucoma y formacion de cataratas dependiente de B(Beta)-amiloide, con dichas proteínas de union a antígenos; composiciones farmacéuticas que comprenden dichas proteínas de union a antígenos; y procedimientos de fabricacion.
UY31520A 2007-12-11 2008-12-09 Proteinas de union a antigenos UY31520A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0724185A GB0724185D0 (en) 2007-12-11 2007-12-11 Antibodies
GB0806230A GB0806230D0 (en) 2008-04-04 2008-04-04 Antibodies
US4383908P 2008-04-10 2008-04-10

Publications (1)

Publication Number Publication Date
UY31520A1 true UY31520A1 (es) 2009-08-03

Family

ID=40547800

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31520A UY31520A1 (es) 2007-12-11 2008-12-09 Proteinas de union a antigenos

Country Status (24)

Country Link
US (2) US8921523B2 (es)
EP (1) EP2222705B1 (es)
JP (2) JP5512537B2 (es)
KR (2) KR101629365B1 (es)
CN (1) CN101970484B (es)
AR (1) AR069610A1 (es)
AU (1) AU2008334637B2 (es)
BR (1) BRPI0819916A2 (es)
CA (1) CA2707859A1 (es)
CL (1) CL2008003655A1 (es)
CO (1) CO6280540A2 (es)
CR (1) CR11561A (es)
DO (1) DOP2010000170A (es)
EA (1) EA022913B1 (es)
ES (1) ES2525704T3 (es)
IL (1) IL206188A0 (es)
MA (1) MA31999B1 (es)
MX (1) MX2010006422A (es)
NZ (1) NZ586003A (es)
PE (1) PE20091449A1 (es)
TW (1) TWI388334B (es)
UY (1) UY31520A1 (es)
WO (1) WO2009074583A1 (es)
ZA (1) ZA201004133B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
RU2604181C2 (ru) 2007-10-05 2016-12-10 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
WO2012016173A2 (en) 2010-07-30 2012-02-02 Ac Immune S.A. Safe and functional humanized antibodies
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
JP2014513678A (ja) * 2011-04-07 2014-06-05 ネオトープ バイオサイエンシーズ リミテッド Ｉｃ３ｂ沈着を伴うタンパク質凝集に関する疾患を治療するための組成物及び方法
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
CA2862999A1 (en) * 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
WO2015006504A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
CA2926856A1 (en) * 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
WO2015120474A1 (en) * 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
JP6951246B2 (ja) * 2014-11-05 2021-10-20 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
CN105542005B (zh) * 2016-02-03 2018-11-09 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
ES2848206T3 (es) * 2016-10-19 2021-08-05 Alexion Pharma Inc Un método de cuantificar C5 sin unir en una muestra
JP7173965B2 (ja) * 2016-10-19 2022-11-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 試料中の非結合Ｃ５ａの定量化方法
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
WO2019074840A1 (en) * 2017-10-09 2019-04-18 Keith Black COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES
KR20210057086A (ko) 2018-09-06 2021-05-20 아칠리온 파르마세우티칼스 인코포레이티드 다니코판의 형태체 형태
US20230126447A1 (en) * 2020-03-10 2023-04-27 Achillion Pharmaceuticals, Inc. Ocular drug depot for complement-mediated disorders
JP2021141861A (ja) * 2020-03-13 2021-09-24 富士フイルム和光純薬株式会社 抗原に対する親和力が向上した抗体のスクリーニング方法および製造方法
CN113929748B (zh) * 2020-07-13 2023-10-20 中国科学技术大学 检测bace1酶活性的试剂盒及用途
CN117131608B (zh) * 2023-10-23 2024-03-15 南京航空航天大学 一种基于最佳环量分布的激励盘方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750349A (en) * 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
WO2001007082A1 (en) * 1999-07-23 2001-02-01 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent
EP1480666B1 (en) 2002-03-05 2012-06-13 Ramot at Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein
EP1633786A4 (en) * 2002-10-09 2007-07-25 Rinat Neuroscience Corp METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
UY29504A1 (es) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
EP2177536B1 (en) * 2006-03-30 2014-06-04 Glaxo Group Limited Antibodies against amyloid-beta peptide
US20090022728A1 (en) * 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases

Also Published As

Publication number Publication date
BRPI0819916A2 (pt) 2015-05-19
CR11561A (es) 2010-09-23
WO2009074583A1 (en) 2009-06-18
CN101970484B (zh) 2014-10-01
KR20100099277A (ko) 2010-09-10
US8921523B2 (en) 2014-12-30
EP2222705A1 (en) 2010-09-01
AR069610A1 (es) 2010-02-03
ES2525704T3 (es) 2014-12-29
US20110014182A1 (en) 2011-01-20
CO6280540A2 (es) 2011-05-20
CL2008003655A1 (es) 2010-04-16
KR101657637B1 (ko) 2016-09-19
MA31999B1 (fr) 2011-01-03
AU2008334637B2 (en) 2014-08-07
PE20091449A1 (es) 2009-10-07
KR20150100964A (ko) 2015-09-02
TW200932267A (en) 2009-08-01
ZA201004133B (en) 2011-11-30
IL206188A0 (en) 2010-12-30
CA2707859A1 (en) 2009-06-18
JP5512537B2 (ja) 2014-06-04
US20090162358A1 (en) 2009-06-25
JP2014177462A (ja) 2014-09-25
EA201000787A1 (ru) 2010-12-30
KR101629365B1 (ko) 2016-06-14
TWI388334B (zh) 2013-03-11
EP2222705B1 (en) 2014-10-22
MX2010006422A (es) 2010-06-25
JP2011506387A (ja) 2011-03-03
EA022913B1 (ru) 2016-03-31
AU2008334637A1 (en) 2009-06-18
CN101970484A (zh) 2011-02-09
DOP2010000170A (es) 2010-08-15
NZ586003A (en) 2012-08-31

Similar Documents

Publication Publication Date Title
UY31520A1 (es) Proteinas de union a antigenos
PH12015501207A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
WO2006091796A3 (en) Compositions and methods for diagnosing and treating retinal diseases
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
NO20083793L (no) Antistoffer mot amyloid-beta peptid
UA116614C2 (uk) Антитіло до фактора d і його застосування
EA200901211A1 (ru) Антигены белка с5 и их применение
BRPI0606172A2 (pt) métodos e composições para o tratamento de distúrbios oculares
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MX2010000351A (es) Compuestos derivados de alquinil fenilo para tratar enfermedades y desordenes oftalmicos.
PE20110023A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
PH12013501456A1 (en) Use of anti~amyloid beta antibody
MX356800B (es) Anticuerpo tau humanizado.
MX337100B (es) Compuestos alcoxi para el tratamiento de enfermedades.
BR122018003623B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
WO2008060364A3 (en) Humani zed antibody against amyloid beta
BRPI0507074A (pt) modalidades aperfeiçoadas para o tratamento de doenças degenerativas da retina
MY171300A (en) Pharmaceutical composition
EP2650308A3 (en) Use of anti-amyloid beta antibody in ocular diseases
MX2009006685A (es) Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos.
MY153738A (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders.
WO2007064727A3 (en) Penetrabodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
UA102368C2 (ru) СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171019